Surgical bailout during TAVR is growing increasingly rare as time goes on. Does that mean it is time to rethink certain coverage policies? A new study and two separate editorials examined this topic in great detail.

SCAI surveyed its members to find out what they thought about potential changes to current TAVR policies. The responses to that survey helped influence the group's official stance. 

Eko Health's Core 300 stethoscope offers noise cancellation, amplification and a real-time display of the patient's heart data. Clinicians can also use the same device for traditional analog listening.

These findings left researchers asking questions about the risk assessment tools clinicians currently use on a daily basis.

These findings call into question the types of screenings firefighters should undergo to detect potential heart problems.

The upcoming Society of Thoracic Surgeons annual meeting in San Diego is scheduled to feature multiple big-name speakers. The four-day event runs Jan. 28-31, 2027. 

CCTA offers clinicians an opportunity to make patient care more efficient. However, interventionalists need to make sure they understand how to properly interpret coronary CT data.

The Freesolve Resorbable Magnesium Scaffold previously received the same designation for below-the-knee interventions. This update covers minimally invasive coronary procedures.

CMS just finalized major updates to its TAVR coverage policies. Could even more change be on the horizon? 

Heart failure patients with a CardioMEMS implant can now monitor their own pulmonary artery pressure readings and receive clinician feedback through a smartphone app.

Orforglipron was linked to consistent weight loss in addition to reductions in waist circumference, systolic blood pressure, triglycerides, non-HDL cholesterol and high-sensitivity C-reactive protein. In terms of safety, it was found to be noninferior to insulin glargine.

Researchers see potential applications in initial staging, evaluation of suspected recurrence and selection of patients for future targeted radioligand therapy. 

Americans were split along party lines, but broadly speaking, federal healthcare agencies are historically unpopular, based on data going back as far as 2003.